Source: Financial Supervisory Service Data Analysis, Retrieval and Transfer System (DART) / 2026-03-30
Disclosure Type: Major Business Matters Related to Investment Decisions
💡 3-Second Summary
On March 30, 2026, Celltrion officially submitted a global Phase 3 clinical trial protocol amendment application to the Ministry of Food and Drug Safety (MFDS) of South Korea for its Keytruda biosimilar candidate, CT-P51, to adjust patient enrollment based on regulatory strategy changes, with the specific target enrollment figures kept confidential until regulatory approval.
📊 1. [Key Disclosure Details & Major Figures Summary]
- Investigational Product & Reference Drug: CT-P51 (Reference Product: Keytruda)
- Indication: Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Clinical Trial Phase: Global Phase 3 Trial Protocol Amendment Filing
- Application Details:
- Filing Date (Fact Confirmation): March 30, 2026 (The date the amendment application was submitted to the MFDS)
- Regulatory Authority: South Korea Ministry of Food and Drug Safety (MFDS)
- Protocol Outline:
- Number of Clinical Trial Subjects: Confidential (Disclosure Deferred)
- Treatment Duration: 2 years of treatment
- Trial Design: Randomized, double-blind, active-controlled, parallel-group, Phase 3 clinical trial
- Clinical Trial Registration Number: EU CT number 2024-514048-98-00
- Details on Deferred Disclosure:
- Deferred Item: Target sample size (number of subjects) within the trial protocol
- Reason for Deferral: Management confidentiality
- Expiration of Deferral: To be maintained until the clinical trial protocol amendment is officially approved by the MFDS
- Filing Purpose: The protocol amendment was submitted to adjust the target sample size as part of changes in the regulatory approval strategy.
📈 2. [Expert Perspective: What This Means for Investors]
- Initial Regulatory Submission Stage: This filing acts as formal verification that Celltrion has initiated the administrative process by submitting the global Phase 3 protocol amendment to the South Korean regulatory authority. It signifies the start of the evaluation period by the MFDS, rather than a final regulatory clearance.
- Confidentiality Regarding Patient Volume: The quantitative adjustment to the target sample size has been classified under “management confidentiality” and is temporarily withheld from the public. Consequently, market participants currently lack access to the exact modified sample size. This figure is scheduled to be disclosed only after the regulatory approval of the protocol amendment is completed.
- Statistical Risks in Clinical Development: As detailed in the standard warning within the disclosure, the statistical probability of an investigational drug successfully navigating to final marketing authorization is approximately 10%. Investors should remain aware that unexpected review variables or outcomes during this Phase 3 evaluation could still lead to adjustments in or abandonment of the commercialization plan.
📝 Editor’s Comment (by K-STOCK Editor)
This corporate filing strictly reports the initial quantitative fact that a global Phase 3 protocol amendment for Celltrion’s Keytruda biosimilar (CT-P51) has been submitted to the MFDS. Because the key parameter regarding the adjusted patient enrollment is explicitly withheld due to management confidentiality, readers should refrain from making speculative assumptions about the scale of the trial or the progress of development. The objective focus for investors is simply noting that the application is under regulatory review and waiting for the official approval announcement that will lift the disclosure deferral and reveal the finalized target sample size.
📢 Disclaimer & Sources
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
